LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Imatinib | 10.0 | uM | LJP6 | 2 | N13 | 72 | hr | 1401 | 4159 | 4223 | 0.9848 | 0.9773 |
| SK-BR-3 | Imatinib | 10.0 | uM | LJP6 | 3 | N13 | 72 | hr | 1401 | 4495 | 4223 | 1.0644 | 1.0964 |
| SK-BR-3 | JNK-9L | 10.0 | uM | LJP6 | 1 | K19 | 72 | hr | 1401 | 1238 | 4223 | 0.2932 | -0.0580 |
| SK-BR-3 | JNK-9L | 10.0 | uM | LJP6 | 2 | K19 | 72 | hr | 1401 | 1128 | 4223 | 0.2671 | -0.0969 |
| SK-BR-3 | JNK-9L | 10.0 | uM | LJP6 | 3 | K19 | 72 | hr | 1401 | 1214 | 4223 | 0.2875 | -0.0665 |
| SK-BR-3 | JW-7-24-1 | 10.0 | uM | LJP6 | 1 | B19 | 72 | hr | 1401 | 1221 | 4223 | 0.2891 | -0.0640 |
| SK-BR-3 | JW-7-24-1 | 10.0 | uM | LJP6 | 2 | B19 | 72 | hr | 1401 | 1110 | 4223 | 0.2628 | -0.1033 |
| SK-BR-3 | JW-7-24-1 | 10.0 | uM | LJP6 | 3 | B19 | 72 | hr | 1401 | 1298 | 4223 | 0.3074 | -0.0367 |
| SK-BR-3 | Lapatinib | 10.0 | uM | LJP6 | 1 | M19 | 72 | hr | 1401 | 1466 | 4223 | 0.3471 | 0.0229 |
| SK-BR-3 | Lapatinib | 10.0 | uM | LJP6 | 2 | M19 | 72 | hr | 1401 | 1987 | 4223 | 0.4705 | 0.2075 |
| SK-BR-3 | Lapatinib | 10.0 | uM | LJP6 | 3 | M19 | 72 | hr | 1401 | 1937 | 4223 | 0.4587 | 0.1898 |
| SK-BR-3 | LDN-193189 | 10.0 | uM | LJP5 | 1 | G01 | 72 | hr | 1401 | 227 | 4223 | 0.0538 | -0.4163 |
| SK-BR-3 | LDN-193189 | 10.0 | uM | LJP5 | 2 | G01 | 72 | hr | 1401 | 639 | 4223 | 0.1513 | -0.2703 |
| SK-BR-3 | LDN-193189 | 10.0 | uM | LJP5 | 3 | G01 | 72 | hr | 1401 | 805 | 4223 | 0.1906 | -0.2114 |
| SK-BR-3 | Linifanib | 10.0 | uM | LJP6 | 1 | J07 | 72 | hr | 1401 | 2017 | 4223 | 0.4776 | 0.2181 |
| SK-BR-3 | Linifanib | 10.0 | uM | LJP6 | 2 | J07 | 72 | hr | 1401 | 2157 | 4223 | 0.5108 | 0.2678 |
| SK-BR-3 | Linifanib | 10.0 | uM | LJP6 | 3 | J07 | 72 | hr | 1401 | 2303 | 4223 | 0.5453 | 0.3195 |
| SK-BR-3 | Linsitinib | 10.0 | uM | LJP5 | 1 | O19 | 72 | hr | 1401 | 2789 | 4223 | 0.6604 | 0.4917 |
| SK-BR-3 | Linsitinib | 10.0 | uM | LJP5 | 2 | O19 | 72 | hr | 1401 | 3077 | 4223 | 0.7286 | 0.5938 |
| SK-BR-3 | Linsitinib | 10.0 | uM | LJP5 | 3 | O19 | 72 | hr | 1401 | 3359 | 4223 | 0.7954 | 0.6938 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP5 | 1 | C19 | 72 | hr | 1401 | 80 | 4223 | 0.0189 | -0.4684 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP5 | 2 | C19 | 72 | hr | 1401 | 122 | 4223 | 0.0289 | -0.4535 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP5 | 3 | C19 | 72 | hr | 1401 | 73 | 4223 | 0.0173 | -0.4709 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP6 | 1 | C19 | 72 | hr | 1401 | 94 | 4223 | 0.0223 | -0.4634 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP6 | 2 | C19 | 72 | hr | 1401 | 94 | 4223 | 0.0223 | -0.4634 |